A comprehensive analysis for pharma IP teams, portfolio managers, payer strategy leads, and institutional investors examining the structural economics, IP […]

An evidence-based analysis of FDA-approved oncology drug economics, patent strategy, and what the numbers actually mean for payers, investors, and

Recent successful drug launches indicate a trend toward more specialized, high-priced drugs that treat less-common medical conditions.

Prescription drugs are expensive to develop, and many intermediaries stand between patients and drug makers. Here’s where the money goes.

1. Why This Matters Now Rare disease drugs now account for 52% of all new molecular entities (NMEs) approved by

A Comprehensive Industry Report regarding the Technological, Economic, and Regulatory Transformation of the Pharmaceutical Sector (2025-2030) Executive Summary: The End

For IP counsel, portfolio managers, R&D leads, and institutional investors who need to move faster than the competition. Why Drug

1. The R&D Productivity Crisis: What the Numbers Actually Say The pharmaceutical industry’s core operating model has a compounding cost